of new-onset AF.
9)
Classical anti-arrhythmic drugs are often characterized by several adverse effects and relative inefficacy. 5) Safer and more efficacious therapeutic agents are needed for AF prevention. 9) It has been shown that "upstream therapies", which aim at reversal of atrial substrate derangement, could be used for AF prevention. Accordingly, the current focus has been shifted to non-antiarrhythmic drugs such as statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and omega-3 polyunsaturated fatty acids. An increasing number of animal experiments and clinical studies have investigated the beneficial role of statins in AF prevention, 10)11) and meta-analyses showed that the use of statins was significantly associated with a decreased risk of AF. [12] [13] [14] In addition, a recent guideline suggests that statins could be used for AF prevention in those with heart failure or undergoing cardiac surgery. 15) However, whether statins may prevent AF in patients other than these subgroups remains a subject of debate. This review article focused on the ability of cardiovascular co-morbidity scoring systems in predicting AF prevention by statins.
Heterogeneity Across Studies
Despite increasing evidence supporting the concept of using statins for AF prevention, clinical studies yielded conflicting results.
Meta-analyses of randomized controlled trials and observational studies reveal that statin therapy is useful for primary prevention of AF, [12] [13] [14] but significant heterogeneity exists across these studies. 14)20) For example, in a recent meta-analysis by Fauchier et al., 21) the most significant benefits of statins appear to be the prevention of postoperative AF and secondary prevention of AF. Other metaanalyses are also in agreement, 13)22) and Bang et al. 23) assumed that the AF prevention effect of statins may be diverse in different clinical settings. These findings suggest that underlying co-morbidities may play an important role in selecting suitable patients for statin therapy.
13)
Consequently, the AF preventive effect of statins might be inconsistent in different clinical setting. 27) and the electroanatomical remodeling of the left atrium. 28) Moreover, the findings of our recent nationwide cohort studies suggest that the CHADS2 and CHA2DS2 VASc score can be used to guide the upstream therapy of AF.
29)30)

CHADS 2 /CHA 2 DS 2 VASc Score to Predict Atrial Fibrillation Prevention Outcome
The CHADS2 scoring system, which was initially developed for the risk stratification of strokes in patients with AF, is a convenient way to evaluate the complexity of cardiovascular co-morbidities. Our recent study shows that this score may help in identifying the patients who could benefit most from statin use for AF prevention.
29) The nationwide cohort, which included 27002 elderly hypertensive patients, demonstrates that CHADS2 score is useful for predicting the effectiveness of statins. Patients with a CHADS2 score ≥2 had a 31% risk reduction of AF, but those with CHADS2 score of 1 gained no significant benefits. 29) Another cohort study, which included 171885 patients aged ≥50 years, show identical results. Statin therapy provided no obvious beneficial effect in those with a CHADS2 score of 0 and had the best effect for those with a CHADS2 score of 2. 30) Those with higher CHADS2 score have a higher risk of AF, and gain more benefits from statins therapy than those with a lower CHADS2 score. This implies that the CHADS2 score could be used to guide the upstream therapy for AF prevention. The CHA2DS2VASc scoring system was recently developed for stroke risk stratification in AF patients. Our study shows that patients with a CHA2DS2VASc score ≥1 benefit from statin use, especially those with score ≥3. 30) Those with score of 1 gain 20% AF risk reduction from statin therapy, while those with score of 2 gain 30%, and those with score ≥3 gain 40%. In contrast, the therapy provides no obvious beneficial effect in those with a CHA2DS2VASc score of 0. From this point of view, CHADS2 and CHA2DS2-VASc scores are not only clinical predictors for stroke risk stratification, but are also useful scoring systems for predicting the effectiveness of statin in AF prevention. However, the role of CHADS2 and CHA2DS2VASc score in upstream therapy for AF requires further study.
Possible Mechanisms of Atrial Fibrillation Prevention by Statin
Atrial fibrillation is a progressive disease that depends on the electrophysiological and anatomical remodeling of atrial substrates.
4)31)
Several mechanisms including myocardial inflammation, oxidative stress, endothelial dysfunction, and alternation in ion channel conductance might contribute to atrial substrate remodeling and AF development. 32) Therapeutic approaches aiming at antagonizing atrial remodeling could be of some benefit in the prevention of AF.
33)34)
Recent evidence emphasizes a role for systemic inflammation in the development and persistence of AF, [49] [50] [51] [52] [53] indicate that statin treatment can reduce inflammation, which may explain the potential beneficial effect of statins for AF prevention. These concepts suggest that the anti-arrhythmic effect of statins tend to be more pronounced in patients with more systemic inflammation and damaged atrial tissue. Patients with no systemic inflammation or those with normal atrial substrate are unlikely to benefit from statin therapy for AF prevention. Recent studies demonstrate that CHADS2 score is useful for predicting CRP levels, left atrium thrombus formation, and the prognosis in patients with AF. with high-sensitivity CRP had a better AF protective effect from statin therapy. Therefore, we proposed that those with higher CHADS2 scores have more severe inflammation, and the anti-inflammatory effect of statins may be more obvious in these patients. Furthermore, female gender and vascular disease, differential factors between CHA2DS2VASc and CHADS2 scores, are also related to increasing systemic inflammation. [56] [57] [58] Therefore, patients with higher CHADS2 and CHA2DS2VASc scores may have a more severe inflammation, and the anti-inflammatory effect of statin may be more obvious in these patients. The current data and JUPITER trial support the statin anti-inflammatory hypothesis and provide an explanation of statin's AF prevention effects in patients with high CHADS2 and CHA2DS2VASc scores.
Effect of Statin Type and Gender in Atrial Fibrillation Prevention by Statin
In addition to the effect of patient' characteristics, previous metaanalyses show that there is a type-dependent efficacy of statin in reducing the risk of new-onset AF.
13) A recent nationwide propensity score-matched study from Denmark also indicate that different statins have diverse effect in preventing new-onset AF. 19) In a metaanalysis by Fang et al., 13) the beneficial effect was noted in the atorvastatin and simvastatin subgroup, but not in pravastatin or rosuvastatin subgroup. Our recent study, on 135275 Taiwanese patients, shows that the level of efficacy in reducing the risk of new-onset AF is related to the type of statin. inflammatory and oxidative status. [66] [67] [68] Therefore, the distinct efficacy of different statins between genders might be attributable to a complex mechanism involving atherosclerotic, and inflammatory status. 59) Female patients gain the AF preventive effect from lipophilic statins via modulation of inflammatory and metabolic abnormality, and male patients gain the AF prevention effect from highpotency statins via deceleration the progression of atherosclerotic diseases. The implications of these findings warrant further investigation.
Conclusion
Statin therapy is significantly associated with a decreased risk of AF in selected population. Recent studies suggest that those with higher CHADS2 and CHA2DS2VASc scores will benefit most from statin use for the prevention of AF. Statins provide limited benefits in primary prevention of AF in patients with low CHADS2 and CHA2DS2-VASc scores. The CHADS2 and CHA2DS2VASc scoring systems are useful for identifying the patients who will benefit most from statins for AF prevention. While these clinical evidences mainly come from retrospective cohort studies, more randomized prospective trials are necessary to further support these conclusions.
